Bank Hapoalim BM Makes New Investment in CVS Health Corporation (NYSE:CVS)

Bank Hapoalim BM purchased a new position in CVS Health Corporation (NYSE:CVS - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,975 shares of the pharmacy operator's stock, valued at approximately $269,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hopwood Financial Services Inc. purchased a new position in shares of CVS Health in the 4th quarter worth $29,000. McIlrath & Eck LLC grew its holdings in CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares during the period. Sierra Ocean LLC grew its holdings in CVS Health by 584.8% during the first quarter. Sierra Ocean LLC now owns 719 shares of the pharmacy operator's stock valued at $49,000 after purchasing an additional 614 shares during the period. MV Capital Management Inc. grew its holdings in CVS Health by 63.9% during the first quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator's stock valued at $50,000 after purchasing an additional 289 shares during the period. Finally, Dunhill Financial LLC grew its holdings in CVS Health by 147.2% during the first quarter. Dunhill Financial LLC now owns 749 shares of the pharmacy operator's stock valued at $51,000 after purchasing an additional 446 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Down 1.2%

CVS stock traded down $0.80 during midday trading on Wednesday, reaching $66.14. 1,738,189 shares of the company traded hands, compared to its average volume of 10,791,877. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $72.51. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The business has a 50 day moving average of $65.18 and a 200-day moving average of $61.90. The firm has a market capitalization of $83.66 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 0.95 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.31 earnings per share. As a group, sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Tuesday, July 22nd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.02%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Analyst Ratings Changes

CVS has been the subject of several recent research reports. UBS Group boosted their price target on CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Jefferies Financial Group boosted their price objective on CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Barclays set a $79.00 price objective on CVS Health and gave the company an "overweight" rating in a research report on Monday, June 2nd. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Finally, Piper Sandler boosted their price objective on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $75.06.

Insider Transactions at CVS Health

In related news, Director Guy P. Sansone bought 1,570 shares of the company's stock in a transaction on Thursday, June 5th. The shares were acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the transaction, the director owned 12,007 shares of the company's stock, valued at $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.22% of the company's stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.